Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 16/20 | 0.53 |
| ▸ | CNR2 | P34972 | 8/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MARS1 | P56192 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3888877 | 0.92 | CNR1 (0.55) | CNR1CNR2MARS1 | |
| SCHEMBL3888578 | 0.87 | CNR1 (0.51) | CNR1CNR2 | |
| SCHEMBL13753469 | 0.86 | CNR1 (0.68) | CNR1CNR2ALDH1A1 | |
| SCHEMBL3900102 | 0.86 | CNR1 (0.54) | CNR1CNR2 | |
| SCHEMBL3888545 | 0.85 | CNR1 (0.56) | CNR1CNR2 | |
| SCHEMBL3887711 | 0.85 | CNR1 (0.56) | CNR1CNR2 | |
| SCHEMBL13867155 | 0.84 | CNR1 (0.54) | CNR1CNR2 | |
| SCHEMBL13980444 | 0.84 | CNR1 (0.47) | CNR1CNR2MARS1 | |
| SCHEMBL13867145 | 0.82 | CNR1 (0.56) | CNR1CNR2 | |
| SCHEMBL13867056 | 0.82 | CNR1 (0.56) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524964-B2 | Tetrahydrothiopyrano pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-28 | — | — | US | disclosed |
| US-7524964-B2 | Tetrahydrothiopyrano pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-28 | — | — | US | disclosed |
| EP-1863479-B1 | TETRAHYDROTHIOPYRANO PYRAZOLE CANNABINOID MODULATORS CROSS REFERENCE TO RELATED APPLICATIONS | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-10 | — | — | EP | disclosed |
| EP-1863479-B1 | TETRAHYDROTHIOPYRANO PYRAZOLE CANNABINOID MODULATORS CROSS REFERENCE TO RELATED APPLICATIONS | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-10 | — | — | EP | disclosed |
| US-20080085899-A1 | TETRAHYDROTHIOPYRANO PYRAZOLE CANNABINOID MODULATORS | LIOTTA FINA | 2008-04-10 | — | — | US | disclosed |
| US-20080085899-A1 | TETRAHYDROTHIOPYRANO PYRAZOLE CANNABINOID MODULATORS | LIOTTA FINA | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085899-A1 | TETRAHYDROTHIOPYRANO PYRAZOLE CANNABINOID MODULATORS | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885ALDH1A1 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.